Cell-Based biosensors: A quartz crystal microbalance approach to membrane protein interaction studies

American Laboratory

Volumn 43, Issue 7, 2011, Pages 26-29

  Elovsson, Karin ^a   Pei, Zhichao ^b   Aastrup, Teodor ^a  

^a Attana AB   (Sweden)

^b NORTHWEST A F UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACES; CELL-BASED BIOSENSOR; CENTRAL COMPONENT; CLINICAL TRIAL; DEVELOPMENT PROCESS; DRUG CANDIDATES; DRUG COMPANIES; DRUG DEVELOPMENT; IN-VIVO; MEMBRANE-PROTEIN INTERACTIONS; REAL TIME;

BIOSENSORS; CELL MEMBRANES; QUARTZ;

DRUG INTERACTIONS;

EID: 79960103553     PISSN: 00447749     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (5)

1. Landers, P. Cost of Developing a New Drug Increases to About $1.7 Billion. Wall Street Journal, Dec 2003.
2. Overington, J.; Al-Lazikani, B. et al. How many drug targets are there? Nature Rev. Drug Discov. 2006, 5, 993-6. (Pubitemid 44835126)
3. Kovtun, Y.; Goldmacher, V. Cell killing by antibody-drug conjugates. Cancer Lett. 2007, 255, 232-40. (Pubitemid 47268641)
4. Beck, A. The next generation of antibody- drug conjugates comes of age. Discovery Med. 2010, 10(53), 329-39.
5. Kovacs, A. Molecular interaction studies in cells: exploring biology at a new level. Innovations Pharm. Technol. Jun 2010, 42-6.